Those of us working in the cell and gene therapy space has become used to working in a dynamic and ever-changing industry. However, as funding becomes an increasing problem for start-ups globally, how can cell and gene therapy companies navigate the uncertainty to come out on top?
We never know quite how increasing drug development costs may drain resources, or how risk-averse investors may affect our funding - yet those leading the way in the cell and gene therapy start-up space could offer some inspiration for the next best moves.
Inceptor Bio, a cell therapy biotechnology company that focuses on cancer treatment development across multiple platforms, is making great strides within the gene therapy industry. Centering their work on various novel mechanisms, their work champions enhanced immune cell cancer treatments in tackling tumours and aiding cancer sufferers.
The company’s innovative work has won support even in an uncertain financial space; Inceptor Bio has raised a total of $37 million in Series A financing and has clearly developed an enviable market strategy.
Inceptor Bio’s acquisition of Arranta Bio’s process development and clinical manufacturing site in Florida in 2021 has proven their financial confidence, and their capacity to continue to expand and explore. Following their example of innovation and conviction could be the key to future success and they’re certainly one to watch.
Biotechnology company, Mnemo Therapeutics, works on the development of powerful T-cell therapies, creating proactive and accessible cures for blood cancers and tumours. Having been successful in securing $90 million in 2021, Mnemo have begun expanding into the United States - now working in both France and America to great success.
Working internationally, they have put themselves in a prime position to navigate competitive offers and make the most of differing material and import costs on either side of the ocean. It seems future partnerships with national and international Pharma will help secure a stronger position, and futureproof them for increased drug development, greater consumer access, and further industry growth.
Based in North Carolina, Stride Bio focus on AAV manufacturing to offer top-tier gene therapy solutions to those with life-threatening diseases. Having already developed a stronghold in the cell and gene therapy industry, Stride Bio have been able to truly accelerate their future trajectory in this space of uncertainty that demands innovation. As a company, they are making great strides with accelerated manufacturing production - advancements they were quick to get started on following a successful £81.5million Series B financing round 18 months ago.
Stride Bio’s approach makes it clear that even more established gene therapy industry leaders need to think innovatively and react quickly to maintain success in such a dynamic period of market growth.
In an ever-changing and dynamic industry, established leaders and start-up companies in the cell and gene therapy market have a lot to contend with. Whilst supply lines, funding, and drug advancements may be uncertain; a proactive and innovative approach is key for those looking to not only survive, but thrive.
Clearly, bravery and conviction in the industry separate low-level companies from respected leaders. Steadfast in this ethos, Inceptor Bio, Mnemo Therapeutics and Stride Bio seem set for a great trajectory in the cell and gene therapy space.
Are you interested in discussing the future of cell and gene therapy with me in some more detail? I'd love to hear your insights into the industry as it stands.
Feel free to drop me a message at firstname.lastname@example.org or connect with me on LinkedIn to chat!
Feature in podcasts, articles, videos and more.
In an ever-changing industry, how can cell and gene therapy start-ups remain dynamic to new challenges to not only survive coming changes but thrive? Click to read more.
Are you attracting the very best industry talent to your start-up? For expert advice on how to thrive in today’s life science talent market, watch CM Life Science's latest 30-minute webinar. Click to watch.
Spencer talks to to Vered Caplan, CEO at Orgenesis Inc. about how their Point Of Care (POC) Platform aims to shape the Cell and Gene Therapies (CGT) ecosystem and market. Click here to listen.